Home › NDC Lookup › Ingredients › Trofinetide › 63090-0660-01
Daybue trofinetide 200 mg/mL Solution — NDC 63090-0660-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 63090-0660-01: Daybue trofinetide 200 mg/mL Solution

by Acadia Pharmaceuticals Inc. · 1 BOTTLE, PLASTIC in 1 CARTON / 450 mL in 1 BOTTLE, PLASTIC

This is a package of Daybue trofinetide 200 mg/mL Solution from Acadia Pharmaceuticals Inc., first listed with the FDA Mar 2023 and currently FDA-listed. It is this product's only package size.

🏷️ FDA NDC (as labeled) 63090-660-01 billing pads the product segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Sep 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 63090-660-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
63090 labeler · 660 product · 01 package
Package marketed since
Mar 10, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC)
0363090660012
Medicaid fills, this package
5,287 prescriptions in the last four reported quarters
FDA record last changed
Sep 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 63090-660-01
Product NDC 63090-660
11-digit billing NDC 63090066001
NCPDP billing unit ML — per mL (volume)
UNII Z2ME8F52QL
UPC 0363090660012
Application # NDA217026
SPL Set ID 67e6f2d9-21f6-466f-9def-826c6a4b8257
Mechanism of action Cytochrome P450 3A4 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors
DEA schedule Non-controlled
Marketing category NDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2023-03-10
Route ORAL
Dosage form SOLUTION
Substance TROFINETIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 084510
GCN 53839
HICL code 048773
Ingredient (HICL) Trofinetide
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H1
Therapeutic class — intermediate (HIC2) Drugs Affecting Principally The Brain
HIC3 code H1I
Therapeutic class — specific (HIC3) Glypromate (Gpe) Analogs
AHFS code 28:92.00.00
AHFS class Central Nervous System Agents, Misc.
FDB label name DAYBUE 200 MG/ML SOLUTION
FDB brand name Daybue
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 084510
  • GCN: 53839
  • HICL (First Databank): 048773
  • AHFS class code: 28:92.00.00
  • RxCUI (RxNorm): 2632857
Why two NDCs? The FDA registers this code as 63090-660-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 63090-0660-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Other nervous system drugs class.

Drug family (ATC) Other nervous system drugs
How it works Cytochrome P450 3A4 Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DAYBUE 200 MG/ML SOLUTION Ingredient Trofinetide
📖 What it is MedlinePlus · NLM

Trofinetide is used to treat Rett syndrome (a genetic condition that causes severe developmental and nervous system problems). Trofinetide is an analog of glycine-proline-glutamate (GPE), a protein that occurs naturally in the brain. It is not known exactly how trofinetide works, but it may improve nerve function and structure.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats Rett syndrome in adults and children 2 years and older. It is sold as Daybue and Daybue Stix. Doctors do not yet know exactly how it works in this condition.
  • It is given twice a day, morning and evening, with or without food. It can be taken by mouth or through a G tube. Use a calibrated syringe or dosing cup from the pharmacy, not a ki...
  • If you miss a dose, just give the next one on time. Do not double up. If vomiting happens after a dose, do not give another. Wait for the next scheduled dose, and call your provide...
  • It very likely will be, since most people in studies had it. It is usually mild or moderate. Stop laxatives before starting, keep up fluids, and let your provider know early. Call...
📖 Read our full Trofinetide guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $23.73 $10,678.64 / 450 ml
Medicare drug plans payPart D · Q2 2026 $24.57 $11,055.47 / 450 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
63090-0660-01 You're viewing this Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 450 mL in 1 BOTTLE, PLASTIC 2022-12-31 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Daybue 200 mg/mLthis 63090-0660-01 Acadia 1 bottle — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
First FDA approval
Mar 2023
📍
2026
Currently FDA-listed
3 years listed
🛡️
2043
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Jan 2043. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Mar 10, 2023 RLD RS ⏳ ~16.2 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

When could a generic Daybue arrive?

Our estimate: 2038 to 2039 a wide window

How sure: Toss-up. Still unsettled, because no settlement has been made public yet.

Why then: The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.

That is before the January 2043 date above, which is common: a court ruling or a deal with the brand’s maker often lets a generic in before the last patent runs out.

See the full forecast for generic Daybue →
Patents & exclusivity — FDA Orange Book
US 12492167 — drug substance (U-3556)
US 9212204 — method of use (U-3556)
US 11827600 — drug substance (U-3556)
US 11370755 — drug substance
US 11827600*PED — drug product
US 12492167*PED — drug product
US 9212204*PED — drug product
US 11370755*PED — drug product
Exclusivity NCE
Exclusivity ODE-425
Exclusivity PED
Exclusivity PED
2023 2025 2027 2029 2031 2033 2035 2037 2039 2041 2043
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (8)
PatentTypeUse codeExpires
US 12492167 ↗ Drug substance U-3556 Jul 12, 2042
US 9212204 ↗ Method of use U-3556 Jan 27, 2032
US 11827600 ↗ Drug substance U-3556 Jul 12, 2042
US 11370755 ↗ Drug substance — Aug 3, 2040
US 11827600*PED ↗ Drug product — Jan 12, 2043
US 12492167*PED ↗ Drug product — Jan 12, 2043
US 9212204*PED ↗ Drug product — Jul 27, 2032
US 11370755*PED ↗ Drug product — Feb 3, 2041
FDA exclusivity
CodeWhat it grantsExpires
NCENew Chemical Entity (5-year)Mar 10, 2028
ODE-425Orphan Drug Exclusivity (7-year)Mar 10, 2030
PEDPediatric Exclusivity (+6 months)Sep 10, 2030
PEDPediatric Exclusivity (+6 months)Sep 10, 2028
Common questions
Is there a generic version of DAYBUE 200 MG/ML SOLUTION?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for DAYBUE 200 MG/ML SOLUTION. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Jan 2043 — an estimate, not a guaranteed launch date. We expect the first generic Daybue between 2038 and 2039. See the forecast.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Pink
FlavorStrawberry
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Trofinetide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII D65DG142WK
    Maltitol is a sugar alcohol made by hydrogenating maltose. It's used as a sweetener and filler in medicines to improve taste and add bulk to tablets and capsules.
  • UNII CR6K9C2NHK
    A synthetic preservative derived from methylparaben. It prevents bacterial and fungal growth in medicines, extending shelf life and maintaining product safety during storage.
  • UNII 625NNB0G9N
    A preservative derived from benzoic acid that prevents bacterial and fungal growth in medicines. It helps keep the product safe and stable throughout its shelf life.
  • UNII 96K6UQ3ZD4
    Sucralose is a synthetic sweetener made from sugar. It's added to medicines to improve taste without adding calories, helping make bitter or unpleasant-tasting drugs easier to take.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAcadia Pharmaceuticals Inc.
Application holderACADIA PHARMACEUTICALS INC
FDA applicationNDA217026 (NDA)
Labeler code63090
First marketedMar 2023
Product typeHuman Prescription Drug
Portfolio6 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 53 words ▾

1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Recommended dosage is twice daily, morning and evening, according to patient weight. DAYBUE or DAYBUE STIX can be given with or without food. ( 2.1 ) Patient Weight Recommended Dosage 9 kg to less than 12 kg 5,000 mg twice daily 12 kg to less than 20 kg 6,000 mg twice daily 20 kg to less than 35 kg 8,000 mg twice daily 35 kg to less than 50 kg 10,000 mg twice daily 50 kg or more 12,000 mg twice daily Can be given orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port.

( 2.1 ) See Full Prescribing Information for instruction on dissolving DAYBUE STIX for oral solution powder. ( 2.3 ) See Full Prescribing Information for dosage recommendations in patients with renal impairment. ( 2.6 , 8.6 )

2.1Recommended Dosage The recommended dosage of DAYBUE or DAYBUE STIX is based on patient weight as shown in Table 1 . Administer DAYBUE or DAYBUE STIX orally or via gastrostomy (G) tube twice daily, in the morning and evening, with or without food. Doses administered via gastrojejunal (GJ) tubes must be administered through the G-port.

Table 1 Recommended Dosage of DAYBUE or DAYBUE STIX in Patients 2 Years of Age and Older Patient Weight Recommended Dosage 9 kg to less than 12 kg 5,000 mg twice daily 12 kg to less than 20 kg 6,000 mg twice daily 20 kg to less than 35 kg 8,000 mg twice daily 35 kg to less than 50 kg 10,000 mg twice daily 50 kg or more 12,000 mg twice daily

2.2DAYBUE Oral Solution Preparation Table 2 includes the volume of DAYBUE oral solution to administer for the corresponding recommended dosage [see Dosage and Administration (2.1 , 2.6) ] . A calibrated measuring device, such as an oral syringe or oral dosing cup, should be obtained from the pharmacy to measure and deliver the prescribed dose accurately. A household measuring cup, teaspoon, or tablespoon is not an adequate measuring device.

Table 2 Recommended Volume of DAYBUE Oral Solution for Administration Dosage DAYBUE Oral Solution Volume 2,500 mg twice daily Dosage for patients with moderate renal impairment [see Dosage and Administration (2.6) ] 12.5 mL twice daily 3,000 mg twice daily 15 mL twice daily 4,000 mg twice daily 20 mL twice daily 5,000 mg twice daily 25 mL twice daily 6,000 mg twice daily 30 mL twice daily 8,000 mg twice daily 40 mL twice daily 10,000 mg twice daily 50 mL twice daily 12,000 mg twice daily 60 mL twice daily Discard any unused DAYBUE oral solution after 14 days of first opening the bottle [see How Supplied/Storage and Handling (16.2) ] .

2.3DAYBUE STIX for Oral Solution Preparation Prior to administration, DAYBUE STIX for oral solution powder must be dissolved in a cold to room temperature water or water-based beverage (juice, tea, lemonade, limeade, or liquid hydration). Preparation of DAYBUE STIX Determine the correct dosage as shown in Table 1 or Table 4 (for patients with moderate renal impairment). Select the appropriate packet strength and number of packets required for each dose, as shown in Table 3 .

Determine the appropriate volume of liquid within the recommended volume range as shown in Table 3 , based on individual patient factors (e.g., age, palatability). Measure the volume of liquid determined in Step 3 by using a calibrated measuring device obtained from the pharmacy. Empty the entire contents of the DAYBUE STIX packet(s) into the measured liquid.

Do not attempt to use partial packets to prepare a dose. Stir until the powder is completely dissolved. Administer the prepared oral solution immediately; do not store for future use.

Discard any prepared oral solution that is not immediately administered. Table 3 Preparation Instructions for DAYBUE STIX for Oral Solution Powder Dose DAYBUE STIX Packet(s) Needed to Prepare Each Dose Volume of Liquid Required to Dissolve Entire Dose Liquid types include water or water-based beverage. , Volume should be selected within the recommended range based on individual patient factors. 5,000 m… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 62 words ▾

3 DOSAGE FORMS AND STRENGTHS Oral solution: 200 mg/mL of a pink to red, strawberry flavored solution. For oral solution: 5,000 mg, 6,000 mg, or 8,000 mg of white, off-white to pinkish powder with strawberry flavor, packaged in individual packets. Oral solution: 200 mg/mL ( 3 ) For oral solution: 5,000 mg, 6,000 mg, or 8,000 mg per packet ( 3 )

⛔ Contraindications 7 words ▾

4 CONTRAINDICATIONS None. None. ( 4 )

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS Diarrhea: Most patients experience diarrhea during treatment with DAYBUE. Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider.

Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected. ( 2.4 , 5.1 ) Weight Loss: Weight loss may occur in patients treated with DAYBUE or DAYBUE STIX. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs.

( 2.4 , 5.2 ) Vomiting: Aspiration and aspiration pneumonia have occurred after vomiting in patients treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management. ( 2.5 , 5.3 )

5.1Diarrhea In Study 1 [see Clinical Studies (14) ] and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases.

In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE. Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed.

Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected [see Dosage and Administration (2.4) ] .

5.2Weight Loss In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs [see Dosage and Administration (2.4) ] .

5.3Vomiting In Study 1, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo [see Adverse Reactions (6.1) ]. Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE.

Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management [see Dosage and Administration (2.5) ] .

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Diarrhea [see Warnings and Precautions (5.1) ] Weight Loss [see Warnings and Precautions (5.2) ] Vomiting [see Warnings and Precautions (5.3) ] The most common adverse reactions (that occurred in at least 10% of DAYBUE-treated patients and at least 2% greater than in placebo) were diarrhea and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Acadia Pharmaceuticals Inc. at 1-844-422-2342 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In controlled and uncontrolled trials in patients with Rett syndrome, 260 patients ages 2 to 40 years were treated with DAYBUE, including 112 patients treated for more than 6 months, 92 patients treated for more than 1 year, and 44 patients treated for more than 2 years.

The safety of DAYBUE STIX has been established from an adequate, well-controlled study, and open-label studies of DAYBUE [see Clinical Studies (14) ] . Below is a display of the adverse reactions of DAYBUE in these studies. Adult and Pediatric Patients with Rett Syndrome 5 Years of Age and Older The safety of DAYBUE was evaluated in a randomized, double-blind, placebo-controlled, 12-week study of patients with Rett syndrome (Study 1) [see Clinical Studies (14) ] .

In Study 1, 93 patients received DAYBUE and 94 patients received placebo. All patients were female, 92% were White, and the mean age was 11 years (range 5 to 20 years). Adverse Reactions Leading to Discontinuation of Treatment Eighteen patients (19%) receiving DAYBUE had adverse reactions that led to withdrawal from the study.

The most common adverse reaction leading to discontinuation of treatment with DAYBUE was diarrhea (15%). Common Adverse Reactions Adverse reactions that occurred in Study 1 in at least 5% of patients treated with DAYBUE and were at least 2% more frequent than in patients on placebo are presented in Table 5 . Table 5 Adverse Reactions in at Least 5% of Patients Treated with DAYBUE and at Least 2% Greater than Placebo in Study 1 Adverse Reaction DAYBUE (N=93) % Placebo (N=94) % Diarrhea 82 20 Vomiting 29 12 Fever 9 4 Seizure 9 6 Anxiety 8 1 Decreased appetite 8 2 Fatigue 8 2 Nasopharyngitis 5 1 Pediatric Patients with Rett Syndrome 2 to 4 Years of Age In an open-label study in pediatric patients 2 to 4 years of age with Rett syndrome (N=15), a total of 13 patients received DAYBUE for at least 12 weeks and 10 patients received DAYBUE for at least 12 months.

Adverse reactions in pediatric patients 2 to 4 years of age treated with DAYBUE were similar to those reported in adult and pediatric patients 5 years of age and older with Rett syndrome in Study 1.

6.2Postmarketing Experience The following adverse reactions have been identified during postapproval use of DAYBUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Aspiration and aspiration pneumonia secondary to vomiting [see Warnings and Precautions (5.3) ] .

🔄 Drug Interactions 121 words ▾

7 DRUG INTERACTIONS Orally administered CYP3A and/or P-gp sensitive substrates for which a small change in substrate plasma concentration may lead to serious adverse reactions: closely monitor for adverse reactions with concomitant use. ( 7.1 )

7.1Effect of DAYBUE and DAYBUE STIX on Other Drugs CYP3A and/or P-gp Substrates Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates where minimal increases in the plasma concentration of these substrates may lead to serious adverse reactions. Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, increased the plasma concentrations of CYP3A and/or P-gp substrates [see Clinical Pharmacology (12.3) ] , which may increase the risk of adverse reactions associated with these substrates.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Severe renal impairment: DAYBUE and DAYBUE STIX are not recommended. ( 8.6 )

8.1Pregnancy Risk Summary There are no adequate data on the developmental risks associated with the use of DAYBUE or DAYBUE STIX in pregnant women. No adverse developmental effects were observed following oral administration of trofinetide to pregnant animals at doses associated with plasma exposures below those used clinically [see Animal Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to pregnant rats during the period of organogenesis resulted in no adverse effects on embryofetal development. At the highest dose tested, plasma exposure (AUC) was less than that in humans at the maximum recommended human dose (MRHD) of 12,000 mg twice daily (24,000 mg/day).

Oral administration of trofinetide (0, 75, 150, or 300 mg/kg twice daily; 0, 150, 300, or 600 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in no adverse effects on embryofetal development. At the highest dose tested, plasma exposure (AUC) was less than that in humans at the MRHD. Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to rats throughout pregnancy and lactation resulted in no adverse effects on pre- and postnatal development.

At the highest dose tested, plasma exposure (AUC) was less than that in humans at the MRHD.

8.2Lactation Risk Summary There is no information regarding the presence of trofinetide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DAYBUE or DAYBUE STIX and any potential adverse effects on the breastfed infant from the treatment or from the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of DAYBUE and DAYBUE STIX for the treatment of Rett syndrome have been established in pediatric patients aged 2 years and older. The safety and effectiveness of DAYBUE for the treatment of Rett syndrome in pediatric patients 5 years of age and older was established in a randomized, double-blind, placebo-controlled, 12-week study (Study 1), which included 108 pediatric patients age 5 to less than 12 years of age and 47 pediatric patients age 12 to less than 17 years of age [see Adverse Reactions (6.1) and Clinical Studies (14) ].

Use of DAYBUE or DAYBUE STIX in patients 2 to 4 years of age is supported by evidence from Study 1 and pharmacokinetic and safety data in 15 pediatric patients 2 to 4 years of age treated with DAYBUE [see Dosage and Administration (2.1) , Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14) ] . Safety and effectiveness in pediatric patients less than 2 years of age have not been established. Juvenile Animal Data Oral administration of trofinetide (0, 150, 300, or 1000 mg/kg twice daily; 0, 300, 600, or 2000 mg/kg/day) to rats from postnatal day (PND) 13-14 through 28 weeks of age resulted in no adverse effects on growth or neurobehavioral function.

Plasma exposures at the highest dose tested were similar to those in pediatric patients at recommended doses. Oral administration of trofinetide (0, 150, 300, or 1000 mg/kg twice daily; 0, 300, 600, or 2000 mg/kg/day) to juvenile rats for 10 weeks beginning on PND 13-14 resulted in no adverse effects on sexual maturation or reproductive function. Plasma exposures at the highest dose tested were similar to those in pediatric patients at recommended doses.

8.5Geriatric Use Clinical studies of DAYBUE did… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~1 min read ▾

8.1Pregnancy Risk Summary There are no adequate data on the developmental risks associated with the use of DAYBUE or DAYBUE STIX in pregnant women. No adverse developmental effects were observed following oral administration of trofinetide to pregnant animals at doses associated with plasma exposures below those used clinically [see Animal Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to pregnant rats during the period of organogenesis resulted in no adverse effects on embryofetal development. At the highest dose tested, plasma exposure (AUC) was less than that in humans at the maximum recommended human dose (MRHD) of 12,000 mg twice daily (24,000 mg/day).

Oral administration of trofinetide (0, 75, 150, or 300 mg/kg twice daily; 0, 150, 300, or 600 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in no adverse effects on embryofetal development. At the highest dose tested, plasma exposure (AUC) was less than that in humans at the MRHD. Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to rats throughout pregnancy and lactation resulted in no adverse effects on pre- and postnatal development.

At the highest dose tested, plasma exposure (AUC) was less than that in humans at the MRHD.

🧒 Pediatric Use ~1 min read ▾

8.4Pediatric Use The safety and effectiveness of DAYBUE and DAYBUE STIX for the treatment of Rett syndrome have been established in pediatric patients aged 2 years and older. The safety and effectiveness of DAYBUE for the treatment of Rett syndrome in pediatric patients 5 years of age and older was established in a randomized, double-blind, placebo-controlled, 12-week study (Study 1), which included 108 pediatric patients age 5 to less than 12 years of age and 47 pediatric patients age 12 to less than 17 years of age [see Adverse Reactions (6.1) and Clinical Studies (14) ].

Use of DAYBUE or DAYBUE STIX in patients 2 to 4 years of age is supported by evidence from Study 1 and pharmacokinetic and safety data in 15 pediatric patients 2 to 4 years of age treated with DAYBUE [see Dosage and Administration (2.1) , Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14) ] . Safety and effectiveness in pediatric patients less than 2 years of age have not been established. Juvenile Animal Data Oral administration of trofinetide (0, 150, 300, or 1000 mg/kg twice daily; 0, 300, 600, or 2000 mg/kg/day) to rats from postnatal day (PND) 13-14 through 28 weeks of age resulted in no adverse effects on growth or neurobehavioral function.

Plasma exposures at the highest dose tested were similar to those in pediatric patients at recommended doses. Oral administration of trofinetide (0, 150, 300, or 1000 mg/kg twice daily; 0, 300, 600, or 2000 mg/kg/day) to juvenile rats for 10 weeks beginning on PND 13-14 resulted in no adverse effects on sexual maturation or reproductive function. Plasma exposures at the highest dose tested were similar to those in pediatric patients at recommended doses.

🧓 Geriatric Use 58 words ▾

8.5Geriatric Use Clinical studies of DAYBUE did not include patients 65 years of age and older to determine whether or not they respond differently from younger patients. This drug is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.

12.2Pharmacodynamics Cardiac Electrophysiology At the maximum recommended dose in healthy adult subjects, trofinetide does not prolong the QT interval to any clinically relevant extent .

12.3Pharmacokinetics DAYBUE STIX for oral solution demonstrated comparable bioavailability to DAYBUE oral solution in adult healthy subjects under fasted state. Trofinetide exhibits linear kinetics with no time- or dose-dependent effect on pharmacokinetic parameters. Systemic exposure to trofinetide was dose-proportional across the studied dose range.

Minimal to no accumulation was observed following multiple-dose administration. Absorption The time to maximum drug concentration (T max ) is about 2 to 3 hours after administration. Based on the mass balance study, at least 84% of the administered dose was absorbed following oral administration of 12,000 mg trofinetide.

Effect of Food Coadministration of trofinetide with a high-fat meal had no impact on the total exposure (AUC 0-inf ) of trofinetide and reduced the peak plasma concentration (C max ) by approximately 20% [see Dosage and Administration (2.1) ] . Distribution Following oral administration, the apparent volume of distribution of trofinetide in adult healthy subjects was approximately 80 L. Trofinetide protein binding in human plasma is less than 6%.

Elimination The effective elimination half-life of orally administered trofinetide in healthy subjects is about 1.5 hours. Metabolism Trofinetide is not significantly metabolized by CYP450 enzymes. Hepatic metabolism is not a significant route of trofinetide elimination.

Excretion Trofinetide is primarily excreted unchanged (approximately 80% of the dose) in urine, with minor excretion in feces. Specific Populations Pediatric Patients The drug exposure of trofinetide in pediatric patients ages 2 to 4 years of age is similar to children older than 4 years and adults when following the recommended dosage [see Dosage and Administration (2.1) ] . Patients with Renal Impairment Based on population PK analysis of clinical trials data, patients with mild renal impairment (eGFR 60 to 89 mL/min/1.73 m 2 ) showed no significant impact on the exposure of trofinetide compared to patients with normal renal function.

Based on a renal impairment study in adult subjects, the effect of moderate renal impairment (eGFR 30 to 59 mL/min) increases the exposure (AUC 0-inf ) of trofinetide approximately 80% compared to patients with normal renal function administered the same dose [see Dosage and Administration (2.6) ] . The effect of severe renal impairment on the exposure of trofinetide has not been investigated [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment The pharmacokinetics in patients with hepatic impairment have not been studied.

However, hepatic impairment is not expected to impact the exposure of trofinetide because hepatic metabolism is not a significant route of trofinetide elimination. Drug Interaction Studies Clinical Studies CYP3A and/or P-gp Substrates: Coadministration of trofinetide 12,000 mg twice daily with 4 mg of loperamide (a moderately sensitive CYP3A substrate and a P-gp substrate) increased the AUC of loperamide by 1.73-fold and the C max by 1.95-fold [see Drug Interactions (7.1) ] . Administration of trofinetide 2 hours prior to loperamide increased the AUC of loperamide by 1.22-fold and the C max by 1.44-fold.

In Vitro Trofinetide is not a substrate of CYP450 enzymes, uridine diphosphate glucuronosyltransferase (UGT), or major drug transporters. Cytochrome P450 (CYP450) Enzymes: Trofinetide inhibits CYP3A [see Drug Interactions (7.1) ] . Trofinetide inhibits CYP1A2, 2B6, 2C8, 2C19, and 2D6, but is not expected to result in clinically significant drug interactions.

Trofinetide does not inhibit CYP2C9. UDP-Glucuronosyltransferase (UGT): Trofinetide in… [Excerpted — this section continues on DailyMed.]

🧬 Mechanism of Action 19 words ▾

12.1Mechanism of Action The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.

📦 How Supplied / Storage and Handling 165 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied DAYBUE (trofinetide) 200 mg/mL oral solution is a pink to red, strawberry flavored solution supplied in a round high-density polyethylene (HDPE) multi-dose bottle with a child-resistant closure containing 450 mL of oral solution (NDC 63090-660-01). DAYBUE STIX (trofinetide) for oral solution is a white, off-white to pinkish powder with a strawberry flavor supplied in multi-layer aluminum packets as follows: Package Configuration and NDC Number Strength Individual Packet Carton of 60 Packets 5,000 mg 63090-663-01 63090-663-60 6,000 mg 63090-664-01 63090-664-60 8,000 mg 63090-665-01 63090-665-60

16.2Storage and Handling DAYBUE Oral Solution Store DAYBUE in an upright position refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the child-resistant cap tightly closed. Discard any unused DAYBUE oral solution after 14 days of first opening the bottle. DAYBUE STIX for Oral Solution Store DAYBUE STIX packets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

📦 Storage and Handling 74 words ▾

16.2Storage and Handling DAYBUE Oral Solution Store DAYBUE in an upright position refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the child-resistant cap tightly closed. Discard any unused DAYBUE oral solution after 14 days of first opening the bottle. DAYBUE STIX for Oral Solution Store DAYBUE STIX packets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

📋 Description 168 words ▾

11 DESCRIPTION DAYBUE oral solution and DAYBUE STIX for oral solution contain the active moiety trofinetide. The chemical name of trofinetide is (2S)-2-{[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino}pentanedioic acid (IUPAC). The molecular formula of trofinetide is C 13 H 21 N 3 O 6 and its molecular weight is 315.33 g/mol.

The chemical structure is shown below. Trofinetide is a white to off-white solid and is freely soluble in water. DAYBUE oral solution is pink to red in color and contains 1 g of trofinetide in each 5 mL of solution (200 mg/mL).

The oral solution also contains FD&C Red No. 40, maltitol, methylparaben sodium, propylparaben sodium, purified water, strawberry flavor, and sucralose as inactive ingredients. DAYBUE STIX for oral solution is a white, off-white to pinkish powder to be dissolved in a cold to room temperature water or water-based beverage before administration and contains 5,000 mg, 6,000 mg, or 8,000 mg of trofinetide in each packet.

The for oral solution powder contains natural strawberry flavor and sucralose as inactive ingredients. Chemical Structure

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the caregiver or patient to read the FDA-approved patient labeling (Patient Information). Preparation and Administration Advise the caregiver or patient that DAYBUE or DAYBUE STIX may be given orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. DAYBUE or DAYBUE STIX may be taken with or without food [see Dosage and Administration (2.1) ].

Instruct the caregiver or patient to obtain a calibrated measuring device, such as an oral syringe or oral dosing cup, from the pharmacy. A household measuring cup, teaspoon, or tablespoon is not an adequate measuring device [see Dosage and Administration (2.2 , 2.3) ] . DAYBUE Oral Solution Instruct the caregiver or patient to discard any unused DAYBUE oral solution after 14 days from first opening the bottle.

DAYBUE STIX for Oral Solution Advise the caregiver or patient that DAYBUE STIX for oral solution powder must be dissolved in a cold to room temperature water or water-based beverage (juice, tea, lemonade, limeade, or liquid hydration) prior to administration [see Dosage and Administration (2.3) ] . Instruct the caregiver or patient on how much water or water-based beverage is needed to dissolve the contents of DAYBUE STIX packet(s). Instruct the caregiver or patient to administer the prepared oral solution immediately and not to store for future use.

Any prepared oral solution not administered must be discarded. Instruct patients to not attempt to use partial packets to prepare a dose. Diarrhea Advise the caregiver or patient that DAYBUE or DAYBUE STIX can cause diarrhea.

Instruct the patient to stop taking laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed [see Warnings and Precautions (5.1) ] . Weight Loss Inform the caregiver or patient that DAYBUE or DAYBUE STIX may cause weight loss and to notify their healthcare provider if weight loss occurs [see Warnings and Precautions (5.2) ] .

Vomiting Advise the caregiver or patient that DAYBUE or DAYBUE STIX can cause vomiting and if vomiting occurs after DAYBUE or DAYBUE STIX administration, do not take an additional dose, but continue with the next scheduled dose [see Dosage and Administration (2.5) ] . Instruct patients to notify their healthcare provider if vomiting does not stop despite medical management [see Warnings and Precautions (5.3) ] . Storage DAYBUE Oral Solution Keep bottles of DAYBUE upright and refrigerated before and after opening.

Do not freeze [see How Supplied/Storage and Handling (16.2) ] .

🧬 Pharmacokinetics ~3 min read ▾

12.3Pharmacokinetics DAYBUE STIX for oral solution demonstrated comparable bioavailability to DAYBUE oral solution in adult healthy subjects under fasted state. Trofinetide exhibits linear kinetics with no time- or dose-dependent effect on pharmacokinetic parameters. Systemic exposure to trofinetide was dose-proportional across the studied dose range.

Minimal to no accumulation was observed following multiple-dose administration. Absorption The time to maximum drug concentration (T max ) is about 2 to 3 hours after administration. Based on the mass balance study, at least 84% of the administered dose was absorbed following oral administration of 12,000 mg trofinetide.

Effect of Food Coadministration of trofinetide with a high-fat meal had no impact on the total exposure (AUC 0-inf ) of trofinetide and reduced the peak plasma concentration (C max ) by approximately 20% [see Dosage and Administration (2.1) ] . Distribution Following oral administration, the apparent volume of distribution of trofinetide in adult healthy subjects was approximately 80 L. Trofinetide protein binding in human plasma is less than 6%.

Elimination The effective elimination half-life of orally administered trofinetide in healthy subjects is about 1.5 hours. Metabolism Trofinetide is not significantly metabolized by CYP450 enzymes. Hepatic metabolism is not a significant route of trofinetide elimination.

Excretion Trofinetide is primarily excreted unchanged (approximately 80% of the dose) in urine, with minor excretion in feces. Specific Populations Pediatric Patients The drug exposure of trofinetide in pediatric patients ages 2 to 4 years of age is similar to children older than 4 years and adults when following the recommended dosage [see Dosage and Administration (2.1) ] . Patients with Renal Impairment Based on population PK analysis of clinical trials data, patients with mild renal impairment (eGFR 60 to 89 mL/min/1.73 m 2 ) showed no significant impact on the exposure of trofinetide compared to patients with normal renal function.

Based on a renal impairment study in adult subjects, the effect of moderate renal impairment (eGFR 30 to 59 mL/min) increases the exposure (AUC 0-inf ) of trofinetide approximately 80% compared to patients with normal renal function administered the same dose [see Dosage and Administration (2.6) ] . The effect of severe renal impairment on the exposure of trofinetide has not been investigated [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment The pharmacokinetics in patients with hepatic impairment have not been studied.

However, hepatic impairment is not expected to impact the exposure of trofinetide because hepatic metabolism is not a significant route of trofinetide elimination. Drug Interaction Studies Clinical Studies CYP3A and/or P-gp Substrates: Coadministration of trofinetide 12,000 mg twice daily with 4 mg of loperamide (a moderately sensitive CYP3A substrate and a P-gp substrate) increased the AUC of loperamide by 1.73-fold and the C max by 1.95-fold [see Drug Interactions (7.1) ] . Administration of trofinetide 2 hours prior to loperamide increased the AUC of loperamide by 1.22-fold and the C max by 1.44-fold.

In Vitro Trofinetide is not a substrate of CYP450 enzymes, uridine diphosphate glucuronosyltransferase (UGT), or major drug transporters. Cytochrome P450 (CYP450) Enzymes: Trofinetide inhibits CYP3A [see Drug Interactions (7.1) ] . Trofinetide inhibits CYP1A2, 2B6, 2C8, 2C19, and 2D6, but is not expected to result in clinically significant drug interactions.

Trofinetide does not inhibit CYP2C9. UDP-Glucuronosyltransferase (UGT): Trofinetide inhibits UGT enzymes, UGT1A9, 2B7, and 2B15. Transporter Systems: Trofinetide inhibits P-gp [see Drug Interactions (7.1) ] , BCRP, and BSEP.

Trofinetide inhibits OAT1, OCT2, OATP1B1, OATP1B3, MATE1, and MATE2-K, but is not expected to result in clinically significant drug interactions. Trofinetide does not inhibit OAT3.

🧬 Pharmacodynamics 26 words ▾

12.2Pharmacodynamics Cardiac Electrophysiology At the maximum recommended dose in healthy adult subjects, trofinetide does not prolong the QT interval to any clinically relevant extent .

🔬 Clinical Studies ~2 min read ▾

14 CLINICAL STUDIES DAYBUE STIX The effectiveness of DAYBUE STIX has been established from an adequate and well-controlled study of DAYBUE for the treatment of Rett syndrome and demonstration of similar pharmacokinetics between DAYBUE STIX for oral solution and DAYBUE oral solution [see Clinical Pharmacology (12.3) ] . Presented below is a display of the efficacy results of the adequate and well-controlled study of DAYBUE in patients with Rett syndrome. DAYBUE The efficacy of DAYBUE for the treatment of Rett syndrome was established in a 12-week randomized, double-blind, placebo-controlled study in patients with Rett syndrome 5 to 20 years of age (Study 1; NCT04181723).

Patients (N=187) had a diagnosis of typical Rett syndrome according to the Rett Syndrome Diagnostic Criteria with a documented disease-causing mutation in the MECP2 gene. Patients were randomized to receive DAYBUE (N=93) or matching placebo (N=94) for 12 weeks. The DAYBUE dosage was based on patient weight to achieve similar exposure in all patients [see Dosage and Administration (2.1) ] .

The co-primary efficacy measures were change from baseline after 12 weeks of treatment in the total score of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) score. The RSBQ is a 45-item rating scale completed by the caregiver that assesses a range of symptoms of Rett syndrome (breathing, hand movements or stereotypies, repetitive behaviors, night-time behaviors, vocalizations, facial expressions, eye gaze, and mood). Each item is scored as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true or often true), with a maximum possible score of 90 points.

Lower scores reflect lesser severity in signs and symptoms of Rett syndrome. The CGI-I is rated by clinicians to assess whether a patient has improved or worsened on a 7-point scale (1=very much improved to 7=very much worse) in which a decrease in score indicates improvement. Treatment with DAYBUE demonstrated a statistically significant difference in favor of DAYBUE as compared to placebo on the co-primary efficacy endpoints, the change from baseline in RSBQ total score, and the CGI-I score at week 12 ( Table 6 , Figure 1 , and Figure 2 ).

Table 6 Summary of Study 1 Efficacy Results Mean Baseline Score (SE) Mean Week 12 Score (SE) LS Mean Change from Baseline to Week 12 (SE) DAYBUE-Placebo Treatment Difference, LS Mean (95% CI) Difference in LS mean from the mixed-effect model for repeated measure analysis p-value CI=confidence interval; LS mean=least-squares mean; SE=standard error RSBQ DAYBUE 43.7 (1.21) 39.9 (1.38) -4.9 (0.94) -3.2 (-5.7, -0.6) 0.018 Placebo 44.5 (1.26) 42.8 (1.42) -1.7 (0.90) CGI-I DAYBUE -- 3.5 (0.08) -- -0.3 (-0.5, -0.1) 0.003 Placebo -- 3.8 (0.06) Figure 1 Change From Baseline in RSBQ Total Score in Study 1 Figure 2 Distribution of CGI-I Scores for Patients Completing Study 1 Figure 1 Figure 2

🧪 Nonclinical Toxicology 118 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Studies to evaluate the carcinogenic potential of trofinetide have not been conducted. Mutagenesis Trofinetide was negative in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster ovary cells) and in vivo (mouse micronucleus) assays. Impairment of Fertility Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to male and female rats prior to and throughout mating and continuing in females through gestation day 7 resulted in no adverse effects on fertility or reproductive function.

Plasma exposures at the highest dose tested were less than that in humans at the maximum recommended human dose of 12,000 mg/dose (24,000 mg/day).

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 115 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Studies to evaluate the carcinogenic potential of trofinetide have not been conducted. Mutagenesis Trofinetide was negative in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster ovary cells) and in vivo (mouse micronucleus) assays. Impairment of Fertility Oral administration of trofinetide (0, 150, 450, or 1000 mg/kg twice daily; 0, 300, 900, or 2000 mg/kg/day) to male and female rats prior to and throughout mating and continuing in females through gestation day 7 resulted in no adverse effects on fertility or reproductive function.

Plasma exposures at the highest dose tested were less than that in humans at the maximum recommended human dose of 12,000 mg/dose (24,000 mg/day).

📄 Patient Package Insert ~3 min read ▾

PATIENT INFORMATION DAYBUE ® (day-BYOO) (trofinetide) oral solution DAYBUE ® STIX (day-BYOO STIX) (trofinetide) for oral solution This Patient Information has been approved by the U.S. Food and Drug Administration Issued: 12/2025 What is DAYBUE or DAYBUE STIX? DAYBUE or DAYBUE STIX are prescription medicines used to treat Rett syndrome in adults and children 2 years of age and older.

It is not known if DAYBUE or DAYBUE STIX is safe and effective in children under 2 years of age. Before taking DAYBUE or DAYBUE STIX, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems. are pregnant or plan to become pregnant. It is not known if DAYBUE or DAYBUE STIX will harm your unborn baby. are breastfeeding or plan to breastfeed.

It is not known if DAYBUE or DAYBUE STIX passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking DAYBUE or DAYBUE STIX. Tell your healthcare provider about all of the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking DAYBUE or DAYBUE STIX with certain medicines may affect the way other medicines work and can cause serious side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take DAYBUE or DAYBUE STIX? Take DAYBUE or DAYBUE STIX exactly as your healthcare provider tells you to take it. If you have kidney problems, talk to your healthcare provider about the right dose of DAYBUE or DAYBUE STIX.

If you take laxatives, stop taking them before starting treatment with DAYBUE or DAYBUE STIX. DAYBUE or DAYBUE STIX may be given by mouth or through a gastrostomy (G) tube. If DAYBUE or DAYBUE STIX is given through a gastrojejunal (GJ) tube, the G-port must be used.

DAYBUE or DAYBUE STIX may be taken with or without food. Your pharmacist should provide an oral syringe or dosing cup that is needed to measure your prescribed dose of DAYBUE or the amount of liquid to mix with DAYBUE STIX powder. A household measuring cup, teaspoon, or tablespoon is not an adequate measuring device.

If you are taking DAYBUE oral solution : Throw away any unused DAYBUE oral solution after 14 days of first opening the bottle. If you are taking DAYBUE STIX for oral solution : Open each packet only when you are ready to use it. DAYBUE STIX powder must be dissolved in cold to room temperature water or water-based beverage (juice, tea, lemonade, or liquid hydration).

Your healthcare provider will tell you how much cold to room temperature water or water-based beverage to use to dissolve the powder in each packet. Empty the entire contents of the DAYBUE STIX packets needed for your prescribed dose into the measured liquid. Do not attempt to use part of a packet.

Stir until the powder is completely dissolved. After the powder is dissolved, take the prepared oral solution right away. Do not store for future use.

Throw away any prepared oral solution that was not taken. Your healthcare provider may change your dose or stop treatment with DAYBUE or DAYBUE STIX if needed. If you vomit after taking a dose of DAYBUE or DAYBUE STIX, do not take another dose to make up for that dose.

Wait and take the next dose at your usual time. Call your healthcare provider if your vomiting does not stop. If you miss a dose of DAYBUE or DAYBUE STIX, skip that dose and take your next dose at your usual time.

Do not take 2 doses to make up the missed dose. What are the possible side effects of DAYBUE or DAYBUE STIX? DAYBUE or DAYBUE STIX may cause side effects, including : Diarrhea.

Diarrhea is a common side effect of DAYBUE or DAYBUE STIX that can sometimes be severe. Diarrhea may cause you to lose too much water from your body (dehydration). Tell your healthcare provider if you have diarrhea while taking DAYBUE or DAYBUE STIX.

Your healthcare provider may ask you to increase the amount you drink or take a… [Excerpted — this section continues on DailyMed.]

📄 Recent Major Changes 13 words ▾

Dosage and Administration ( 2.1 , 2.2 , 2.3 , 2.6 ) 12/2025

📄 Package Label / Principal Display Panel ~2 min read ▾

PRINCIPAL DISPLAY PANEL – 450 ML ORAL SOLUTION BOTTLE LABEL NDC 63090-660-01 450 mL Rx only Daybue™ (trofinetide) oral solution 200 mg/mL Recommended Dosage: See prescribing information. For oral or G-tube administration only. PRINCIPAL DISPLAY PANEL – 450 ML ORAL SOLUTION BOTTLE LABEL

PRINCIPAL DISPLAY PANEL – 450 ML ORAL SOLUTION BOTTLE CARTON NDC 63090-660-01 Daybue™ (trofinetide) oral solution 200 mg/mL Recommended Dosage: See prescribing information. For oral or G-tube administration only. 450 mL Rx only PRINCIPAL DISPLAY PANEL – 450 ML ORAL SOLUTION BOTTLE CARTON

PRINCIPAL DISPLAY PANEL – 5,000 MG FOR ORAL SOLUTION POWDER PACKET NDC 63090-663-01 Daybue ® Stix (trofinetide) for oral solution 5,000 mg For Oral or G-tube administration only Keep out of reach of children Rx Only PRINCIPAL DISPLAY PANEL – 5,000 MG FOR ORAL SOLUTION POWDER PACKET

PRINCIPAL DISPLAY PANEL – 5,000 MG FOR ORAL SOLUTION POWDER CARTON NDC 63090-663-60 Daybue ® Stix (trofinetide) for oral solution 5,000 mg per packet For Oral or G-tube administration only 60 Packets Rx Only PRINCIPAL DISPLAY PANEL – 5,000 MG FOR ORAL SOLUTION POWDER CARTON

PRINCIPAL DISPLAY PANEL – 6,000 MG FOR ORAL SOLUTION POWDER PACKET NDC 63090-664-01 Daybue ® Stix (trofinetide) for oral solution 6,000 mg For Oral or G-tube administration only Keep out of reach of children Rx Only PRINCIPAL DISPLAY PANEL – 6,000 MG FOR ORAL SOLUTION POWDER PACKET

PRINCIPAL DISPLAY PANEL – 6,000 MG FOR ORAL SOLUTION POWDER CARTON NDC 63090-664-60 Daybue ® Stix (trofinetide) for oral solution 6,000 mg per packet For Oral or G-tube administration only 60 Packets Rx Only PRINCIPAL DISPLAY PANEL – 6,000 MG FOR ORAL SOLUTION POWDER CARTON

PRINCIPAL DISPLAY PANEL – 8,000 MG FOR ORAL SOLUTION POWDER PACKET NDC 63090-665-01 Daybue ® Stix (trofinetide) for oral solution 8,000 mg For Oral or G-tube administration only Keep out of reach of children Rx Only PRINCIPAL DISPLAY PANEL – 8,000 MG FOR ORAL SOLUTION POWDER PACKET

PRINCIPAL DISPLAY PANEL – 8,000 MG FOR ORAL SOLUTION POWDER CARTON NDC 63090-665-60 Daybue ® Stix (trofinetide) for oral solution 8,000 mg per packet For Oral or G-tube administration only 60 Packets Rx Only PRINCIPAL DISPLAY PANEL – 8,000 MG FOR ORAL SOLUTION POWDER CARTON

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
5.3K
Units reimbursed last 4 qtrs
10.6M
Gross reimbursed last 4 qtrs
$252.71M
Avg / prescription
$47,798.44
Avg / unit
$23.7303
Latest quarter Q1 2026
1.3KRx
Fee-for-service vs managed care ⓘ
51% FFS 49% MCO
Fee-for-service · 2,704 Rx Managed care · 2,583 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 196,200 units · 2,512 per 100k residents WA Idaho: 160,650 units · 8,180 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 220,500 units · 3,843 per 100k residents MN Wisconsin: 124,200 units · 2,102 per 100k residents WI Michigan: 316,350 units · 3,152 per 100k residents MI New York: 391,950 units · 2,003 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 257,400 units · 2,051 per 100k residents IL Indiana: 207,900 units · 3,030 per 100k residents IN Ohio: 388,350 units · 3,295 per 100k residents OH Pennsylvania: 369,450 units · 2,850 per 100k residents PA New Jersey: 266,850 units · 2,872 per 100k residents NJ Massachusetts: 24,300 units · 347 per 100k residents MA California: 1,283,400 units · 3,294 per 100k residents CA Utah: no data reported UT Colorado: 407,700 units · 6,936 per 100k residents CO Nebraska: 231,750 units · 11,716 per 100k residents NE Missouri: 87,300 units · 1,409 per 100k residents MO Kentucky: 233,550 units · 5,160 per 100k residents KY West Virginia: no data reported WV Virginia: 184,950 units · 2,122 per 100k residents VA Maryland: 184,500 units · 2,985 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 158,850 units · 2,138 per 100k residents AZ New Mexico: 141,750 units · 6,705 per 100k residents NM Kansas: 159,300 units · 5,418 per 100k residents KS Arkansas: 29,700 units · 968 per 100k residents AR Tennessee: 347,400 units · 4,875 per 100k residents TN North Carolina: 250,200 units · 2,309 per 100k residents NC South Carolina: 125,100 units · 2,328 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 366,750 units · 8,018 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 230,850 units · 2,093 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 1,326,150 units · 4,348 per 100k residents TX Florida: 466,650 units · 2,064 per 100k residents FL
Units reimbursed · per 100k residents
34711,716
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nebraska 11,716 /100k
2 Idaho 8,180 /100k
3 Louisiana 8,018 /100k
4 Colorado 6,936 /100k
5 New Mexico 6,705 /100k
6 Kansas 5,418 /100k
7 Kentucky 5,160 /100k
8 Tennessee 4,875 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Daybue — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Daybue. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$12.37M
Claims incl. refills
201
Beneficiaries
84
Spend / beneficiary
$147,221.57
Spend / claim
$61,525.43
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Daybue (this brand).

Top reported reactions

Diarrhoea3,750
Underdose2,082
Vomiting1,187
Seizure882
Constipation700
Product Use Complaint655
Weight Decreased609

Age at onset

Infant1
Child15
Adolescent3
Adult12

Reporter sex

6,891 reports
Male · 4%
Female · 96%

Serious outcomes

Hospitalization840
Death42
Life-threatening35
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 2,524 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Acadia Pharmaceuticals Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Acadia Pharmaceuticals Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.